Abstract
Panitumumab plus irinotecan is not active for the treatment of esophageal adenocarcinoma. Esophageal adenocarcinoma (EAC) is a lethal cancer with increasing incidence. Panitumumab (Pa) is a fully humanized IgG2 monoclonal antibody against human EGFR. Cetuximab (Cx) combined with irinotecan (Ir) is active for second-line treatment of colorectal cancer. This phase II study was designed to evaluate Pa plus Ir as second-line therapy for advanced EAC. The primary endpoint was response rate (RR). Patients with one prior treatment were given Pa 9 mg/m2 on day 1 and Ir 125 mg/m2 on days 1 and 8 of each 21-day cycle. Inclusion criteria were confirmed EAC, measurable disease, no prior Ir or Pa, performance status <2, and normal organ function. Twenty-four patients were enrolled; 18 were eligible and evaluable. These patients were all white, with a median age of 62.5 years (range, 33-79 years), and included 15 men and 3 women. The median number of cycles was 3.5. The most common grade 1-2 adverse events were fatigue, diarrhea, anemia, leukopenia, and hypoalbuminemia. Grade 3-4 adverse events included hematologic, gastrointestinal, electrolyte, rash, fatigue, and weight loss. The median follow-up was 7.2 months (range, 2.3-14 months). Ther...Continue Reading
References
Mar 1, 1989·Controlled Clinical Trials·R Simon
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John Mendelsohn, Jose Baselga
Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Kenneth A FoonGisela M Schwab
Apr 18, 2007·British Journal of Cancer·E van MeertenA van der Gaast
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemRafael G Amado
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jaffer A AjaniUNKNOWN V-325 Study Group
Jan 4, 2008·The New England Journal of Medicine·David CunninghamUNKNOWN Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel TepperRobert Mayer
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Sep 24, 2009·British Journal of Cancer·C PintoA A Martoni
Aug 24, 2010·Lancet·Yung-Jue BangUNKNOWN ToGA Trial Investigators
May 9, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemManish A Shah
Jun 1, 2012·The New England Journal of Medicine·P van HagenUNKNOWN CROSS Group
Feb 5, 2013·Lancet·Arjun PennathurJames D Luketich
Apr 19, 2013·The Lancet Oncology·Florian LordickUNKNOWN Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators
Apr 19, 2013·The Lancet Oncology·Tom WaddellYolanda Barbachano
Oct 8, 2013·Lancet·Charles S FuchsUNKNOWN REGARD Trial Investigators
Jul 6, 2014·The Lancet Oncology·Yu SunakawaYasutsuna Sasaki
Sep 23, 2014·The Lancet Oncology·Hansjochen WilkeUNKNOWN RAINBOW Study Group
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Sep 30, 2017·The Lancet Oncology·Daniel V T CatenacciDavid Cunningham
Nov 9, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toshihiko DoiJaafar Bennouna
Citations
Apr 2, 2019·Current Topics in Medicinal Chemistry·Wenjie Wang, Yuk-Ching Tse-Dinh
Dec 29, 2020·Frontiers in Oncology·Steven B MaronYelena Y Janjigian
Jun 4, 2019·Biochimica Et Biophysica Acta. Reviews on Cancer·Ravindran Caspa GokulanAlexander I Zaika